BRANFORD, Conn., April 1, 2016 /PRNewswire/ -- Wren Laboratories, a CLIA laboratory focused on the advancement of liquid biopsy based gene expression analysis assays in neuroendocrine disease, will present on Saturday, April 2, 2016, at ENDO 2016, the Endocrine Society's 98th Annual Meeting & Expo being held in Boston, MA. During this presentation Wren Laboratories will share the results of their collaborative work with the Hypertension Institute of Cardiology in Warsaw, the Maria Skłodowska-Curie Memorial Cancer Center, and the University of Warmia and Mazury.
The presentation is centered on the clinical and translational research focused on the improvement in the clinical management of paragangliomas and pheochromocytomas through the early detection of disease progression. The 51-gene NETest was used in a cohort of 24 patients, and it was determined through transcript analysis that patients with progressive and metastatic disease exhibit elevated gene expression levels when compared to those with clinically stable, localized diseases.
"The notion of using a minimally invasive blood test to provide informative data about the disease status of our patients is a novel concept, and we are seeing clinical utility in this approach," stated Dr. Agnieszka Kolasinska-Ćwikła of the Maria Skłodowska-Curie Memorial Cancer Center in Warsaw, Poland.
The NETest is an mRNA expression assay targeting 51 genes associated with the tumor metabolism and proliferation. Mathematical assessment of the 51 genes provides a score that can be used to define disease status (progressive vs stable). The NETest score was developed for well-differentiated, low grade (WHO Grade I and II) gastroenteropancreatic NETs. It is scaled from 0 (lowest risk) to 100% (highest). Its intended use is to aid clinicians in their assessment of NET tumor activity and possible disease progression.
About Wren Laboratories
Wren Laboratories is a CLIA Laboratory located in Branford, Connecticut, that collaborates with the neuroendocrine community on the improvement of patient care through the advancement of molecular diagnostics.
MEDIA CONTACT:
Janel Noblin, GEM Advertising, janel@GEM-Advertising.com, 1-844-436-8326x709
SOURCE Wren Laboratories